Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Current State of and Future Opportunities for Prediction in Microbiome Research: Report from the Mid-Atlantic Microbiome Meet-up in Baltimore on 9 January 2019.

Sakowski E, Uritskiy G, Cooper R, Gomes M, McLaren MR, Meisel JS, Mickol RL, Mintz CD, Mongodin EF, Pop M, Rahman MA, Sanchez A, Timp W, Vela JD, Wolz CM, Zackular JP, Chopyk J, Commichaux S, Davis M, Dluzen D, Ganesan SM, Haruna M, Nasko D, Regan MJ, Sarria S, Shah N, Stacy B, Taylor D, DiRuggiero J, Preheim SP.

mSystems. 2019 Oct 8;4(5). pii: e00392-19. doi: 10.1128/mSystems.00392-19.

2.

Extracellular RNA profiles with human age.

Dluzen DF, Noren Hooten N, De S, Wood WH 3rd, Zhang Y, Becker KG, Zonderman AB, Tanaka T, Ferrucci L, Evans MK.

Aging Cell. 2018 Aug;17(4):e12785. doi: 10.1111/acel.12785. Epub 2018 May 24.

3.

MicroRNAs Modulate Oxidative Stress in Hypertension through PARP-1 Regulation.

Dluzen DF, Kim Y, Bastian P, Zhang Y, Lehrmann E, Becker KG, Noren Hooten N, Evans MK.

Oxid Med Cell Longev. 2017;2017:3984280. doi: 10.1155/2017/3984280. Epub 2017 Jun 4.

4.

Racial differences in microRNA and gene expression in hypertensive women.

Dluzen DF, Noren Hooten N, Zhang Y, Kim Y, Glover FE, Tajuddin SM, Jacob KD, Zonderman AB, Evans MK.

Sci Rep. 2016 Oct 25;6:35815. doi: 10.1038/srep35815.

5.

Extracellular RNA in aging.

Dluzen DF, Noren Hooten N, Evans MK.

Wiley Interdiscip Rev RNA. 2017 Mar;8(2). doi: 10.1002/wrna.1385. Epub 2016 Aug 17. Review.

6.

Regulation of UGT2B Expression and Activity by miR-216b-5p in Liver Cancer Cell Lines.

Dluzen DF, Sutliff AK, Chen G, Watson CJ, Ishmael FT, Lazarus P.

J Pharmacol Exp Ther. 2016 Oct;359(1):182-93. doi: 10.1124/jpet.116.235044. Epub 2016 Jul 29.

7.

Metformin-mediated increase in DICER1 regulates microRNA expression and cellular senescence.

Noren Hooten N, Martin-Montalvo A, Dluzen DF, Zhang Y, Bernier M, Zonderman AB, Becker KG, Gorospe M, de Cabo R, Evans MK.

Aging Cell. 2016 Jun;15(3):572-81. doi: 10.1111/acel.12469. Epub 2016 Mar 17.

8.

Posttranscriptional Regulation of the Inflammatory Marker C-Reactive Protein by the RNA-Binding Protein HuR and MicroRNA 637.

Kim Y, Noren Hooten N, Dluzen DF, Martindale JL, Gorospe M, Evans MK.

Mol Cell Biol. 2015 Dec;35(24):4212-21. doi: 10.1128/MCB.00645-15. Epub 2015 Oct 5.

9.

A novel biomechanical analysis of gait changes in the MPTP mouse model of Parkinson's disease.

Geldenhuys WJ, Guseman TL, Pienaar IS, Dluzen DE, Young JW.

PeerJ. 2015 Aug 11;3:e1175. doi: 10.7717/peerj.1175. eCollection 2015.

10.

MicroRNA regulation of the major drug-metabolizing enzymes and related transcription factors.

Dluzen DF, Lazarus P.

Drug Metab Rev. 2015 Aug;47(3):320-34. doi: 10.3109/03602532.2015.1076438. Epub 2015 Aug 20. Review.

11.

Methyl Yellow: A Potential Drug Scaffold for Parkinson's Disease.

Geldenhuys WJ, Kochi A, Lin L, Sutariya V, Dluzen DE, Van der Schyf CJ, Lim MH.

Chembiochem. 2014 Jul 21;15(11):1591-1598. doi: 10.1002/cbic.201300770. Epub 2014 Jul 8.

12.

Impact of circadian nuclear receptor REV-ERBα on midbrain dopamine production and mood regulation.

Chung S, Lee EJ, Yun S, Choe HK, Park SB, Son HJ, Kim KS, Dluzen DE, Lee I, Hwang O, Son GH, Kim K.

Cell. 2014 May 8;157(4):858-68. doi: 10.1016/j.cell.2014.03.039.

13.

Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p.

Dluzen DF, Sun D, Salzberg AC, Jones N, Bushey RT, Robertson GP, Lazarus P.

J Pharmacol Exp Ther. 2014 Mar;348(3):465-77. doi: 10.1124/jpet.113.210658. Epub 2014 Jan 7.

14.

Importance of UDP-glucuronosyltransferases 2A2 and 2A3 in tobacco carcinogen metabolism.

Bushey RT, Dluzen DF, Lazarus P.

Drug Metab Dispos. 2013 Jan;41(1):170-9. doi: 10.1124/dmd.112.049171. Epub 2012 Oct 18.

15.

Dimebon attenuates methamphetamine, but not MPTP, striatal dopamine depletion.

Geldenhuys WJ, Darvesh AS, Dluzen DE.

Neurochem Int. 2012 Jun;60(8):806-8. doi: 10.1016/j.neuint.2012.03.013. Epub 2012 Mar 28.

PMID:
22710395
16.

Markers associated with testosterone enhancement of methamphetamine-induced striatal dopaminergic neurotoxicity.

Buletko AB, Dluzen DE, McDermott JL, Darvesh AS, Geldenhuys WJ.

Neurotoxicol Teratol. 2012 May-Jun;34(3):338-43. doi: 10.1016/j.ntt.2012.03.003. Epub 2012 Apr 1.

PMID:
22521941
17.

Nomifensine alters sex differences in striatal dopaminergic function.

Poth LS, O'Connell BP, McDermott JL, Dluzen DE.

Synapse. 2012 Aug;66(8):686-93. doi: 10.1002/syn.21554. Epub 2012 Apr 17.

PMID:
22389194
18.

Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease.

Bourque M, Dluzen DE, Di Paolo T.

Front Neuroendocrinol. 2012 Apr;33(2):169-78. doi: 10.1016/j.yfrne.2012.02.003. Epub 2012 Mar 1. Review.

PMID:
22387674
19.

Sex and temporally-dependent effects of methamphetamine toxicity on dopamine markers and signaling pathways.

Bourque M, Dluzen DE, Di Paolo T.

Neuropharmacology. 2012 Jun;62(7):2363-72. doi: 10.1016/j.neuropharm.2012.02.009. Epub 2012 Feb 21.

PMID:
22369785
20.

Markers associated with sex differences in methamphetamine-induced striatal dopamine neurotoxicity.

Dluzen DE, McDermott JL, Bourque M, Di Paolo T, Darvesh AS, Buletko AB, Laping NJ.

Curr Neuropharmacol. 2011 Mar;9(1):40-4. doi: 10.2174/157015911795017399.

21.

Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease.

Al Sweidi S, Sánchez MG, Bourque M, Morissette M, Dluzen D, Di Paolo T.

J Neuroendocrinol. 2012 Jan;24(1):48-61. doi: 10.1111/j.1365-2826.2011.02193.x. Review.

PMID:
21790809
22.

Structure-activity relationship and docking studies of thiazolidinedione-type compounds with monoamine oxidase B.

Carroll RT, Dluzen DE, Stinnett H, Awale PS, Funk MO, Geldenhuys WJ.

Bioorg Med Chem Lett. 2011 Aug 15;21(16):4798-803. doi: 10.1016/j.bmcl.2011.06.060. Epub 2011 Jun 21.

PMID:
21742494
23.

Parity decreases methamphetamine-induced striatal dopaminergic perturbation.

Dluzen DE.

Neurochem Int. 2011 Aug;59(2):101-3. doi: 10.1016/j.neuint.2011.04.005. Epub 2011 Jun 14.

PMID:
21693145
24.

The effect of freezing and extraction upon striatal dopaminergic function.

Dluzen DE.

J Neurosci Methods. 2011 May 15;198(1):23-8. doi: 10.1016/j.jneumeth.2011.02.031. Epub 2011 Mar 12.

PMID:
21392526
25.

Sex differences in methamphetamine toxicity in mice: effect on brain dopamine signaling pathways.

Bourque M, Liu B, Dluzen DE, Di Paolo T.

Psychoneuroendocrinology. 2011 Aug;36(7):955-69. doi: 10.1016/j.psyneuen.2010.12.007. Epub 2011 Jan 13.

PMID:
21236583
26.

BCL-2 is a downstream target of ATF5 that mediates the prosurvival function of ATF5 in a cell type-dependent manner.

Dluzen D, Li G, Tacelosky D, Moreau M, Liu DX.

J Biol Chem. 2011 Mar 4;286(9):7705-13. doi: 10.1074/jbc.M110.207639. Epub 2011 Jan 6.

27.

Male/Female differences in neuroprotection and neuromodulation of brain dopamine.

Bourque M, Dluzen DE, Di Paolo T.

Front Endocrinol (Lausanne). 2011 Sep 30;2:35. doi: 10.3389/fendo.2011.00035. eCollection 2011.

28.

Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.

Chen G, Giambrone NE Jr, Dluzen DF, Muscat JE, Berg A, Gallagher CJ, Lazarus P.

Cancer Res. 2010 Oct 1;70(19):7543-52. doi: 10.1158/0008-5472.CAN-09-4582. Epub 2010 Sep 28.

29.

Age-related changes in nigrostriatal dopaminergic function in heterozygous mutant dopamine transporter knock-out mice.

Dluzen DE, Ji J, McDermott JL.

Neurosci Lett. 2010 May 31;476(2):66-9. doi: 10.1016/j.neulet.2010.04.004. Epub 2010 Apr 9.

PMID:
20382201
30.

Relationships among gender, age, time, and temperature in methamphetamine-induced striatal dopaminergic neurotoxicity.

Dluzen DE, McDermott JL, Darvesh AS.

Neuroscience. 2010 Jun 2;167(4):985-93. doi: 10.1016/j.neuroscience.2010.02.076. Epub 2010 Mar 6.

PMID:
20211701
31.

Effects of a novel dopamine uptake inhibitor upon extracellular dopamine from superfused murine striatal tissue.

Geldenhuys WJ, Bezuidenhout LM, Dluzen DE.

Eur J Pharmacol. 2009 Oct 1;619(1-3):38-43. doi: 10.1016/j.ejphar.2009.08.012. Epub 2009 Aug 15.

PMID:
19686731
32.

Genetic alteration in the dopamine transporter differentially affects male and female nigrostriatal transporter systems.

Ji J, Bourque M, Di Paolo T, Dluzen DE.

Biochem Pharmacol. 2009 Dec 1;78(11):1401-11. doi: 10.1016/j.bcp.2009.07.004. Epub 2009 Jul 15.

PMID:
19615345
33.

Neuroprotective actions of sex steroids in Parkinson's disease.

Bourque M, Dluzen DE, Di Paolo T.

Front Neuroendocrinol. 2009 Jul;30(2):142-57. doi: 10.1016/j.yfrne.2009.04.014. Epub 2009 May 3. Review.

PMID:
19410597
34.

Sex differences in dopamine- and vesicular monoamine-transporter functions.

Dluzen DE, McDermott JL.

Ann N Y Acad Sci. 2008 Oct;1139:140-50. doi: 10.1196/annals.1432.010.

PMID:
18991858
35.

Testosterone enhances dopamine depletion by methamphetamine in male, but not female, mice.

Lewis C, Dluzen DE.

Neurosci Lett. 2008 Dec 19;448(1):130-3. doi: 10.1016/j.neulet.2008.10.011. Epub 2008 Oct 7.

PMID:
18852023
36.

Differences in reserpine-induced striatal dopamine output and content between female and male mice: implications for sex differences in vesicular monoamine transporter 2 function.

Dluzen DE, Bhatt S, McDermott JL.

Neuroscience. 2008 Jul 17;154(4):1488-96. doi: 10.1016/j.neuroscience.2008.04.051. Epub 2008 May 2.

PMID:
18515015
37.

Gender differences in methamphetamine use and responses: a review.

Dluzen DE, Liu B.

Gend Med. 2008 Mar;5(1):24-35. Review.

PMID:
18420163
38.

Sex differences in striatal dopaminergic function within heterozygous mutant dopamine transporter knock-out mice.

Ji J, Dluzen DE.

J Neural Transm (Vienna). 2008 Jun;115(6):809-17. doi: 10.1007/s00702-007-0017-0. Epub 2008 Jan 15.

PMID:
18197357
39.

Aging and sex differences in striatal dopaminergic function.

McDermott JL, Dluzen DE.

Neuroscience. 2007 Oct 26;149(2):401-8. Epub 2007 Sep 1.

PMID:
17900817
40.

Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity.

Bourque M, Liu B, Dluzen DE, Di Paolo T.

Biochem Pharmacol. 2007 Nov 1;74(9):1413-23. Epub 2007 Jul 14.

PMID:
17825264
41.
42.

Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.

Liu B, Dluzen DE.

Clin Exp Pharmacol Physiol. 2007 Jul;34(7):555-65. Review.

PMID:
17581209
43.

Protective effects of ginsenoside Rg2 against glutamate-induced neurotoxicity in PC12 cells.

Li N, Liu B, Dluzen DE, Jin Y.

J Ethnopharmacol. 2007 May 22;111(3):458-63. Epub 2006 Dec 20.

PMID:
17257792
44.

Estrogen, testosterone, and methamphetamine toxicity.

Dluzen DE, McDermott JL.

Ann N Y Acad Sci. 2006 Aug;1074:282-94. Review.

PMID:
17105924
45.

Gender differences in Parkinson's disease.

Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, Eshuis S, Booij J, Dluzen DE, Horstink MW.

J Neurol Neurosurg Psychiatry. 2007 Aug;78(8):819-24. Epub 2006 Nov 10.

46.

Sex differences in methamphetamine-evoked striatal dopamine of mice are reversed by nomifensine.

Kunnathur V, Shemisa K, Liu B, Salvaterra TJ, Dluzen DE.

Neurotoxicol Teratol. 2006 Sep-Oct;28(5):557-62. Epub 2006 Jul 28.

PMID:
16978834
49.

Testosterone modulation of striatal dopamine output in orchidectomized mice.

Shemisa K, Kunnathur V, Liu B, Salvaterra TJ, Dluzen DE.

Synapse. 2006 Oct;60(5):347-53.

PMID:
16838357
50.

Supplemental Content

Loading ...
Support Center